Article thumbnail

A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR

By Kelly Broen, Henriette Levenga, Johanna Vos, Kees van Bergen, Hanny Fredrix, Annelies Greupink-Draaisma, Michel Kester, J. H. Frederik Falkenburg, Pieter de Mulder, Theo de Witte, Marieke Griffioen and Harry Dolstra

Abstract

Nonmyeloablative allogeneic stem cell transplantation (SCT) can induce remission in patients with renal cell carcinoma (RCC), but this graft-versus-tumor (GVT) effect is often accompanied by graft-versus-host disease (GVHD). Here, we evaluated minor histocompatibility antigen (MiHA)-specific T cell responses in two patients with metastatic RCC who were treated with reduced-intensity conditioning SCT followed by donor lymphocyte infusion (DLI). One patient had stable disease and emergence of SMCY.A2-specific CD8+ T cells was observed after DLI with the potential of targeting SMCY-expressing RCC tumor cells. The second patient experienced partial regression of lung metastases from whom we isolated a MiHA-specific CTL clone with the capability of targeting RCC cell lines. Whole genome association scanning revealed that this CTL recognizes a novel HLA-B7-restricted MiHA, designated ZAPHIR, resulting from a polymorphism in the splice donor site of the ZNF419 gene. Tetramer analysis showed that emergence of ZAPHIR-specific CD8+ T cells in peripheral blood occurred in the absence of GVHD. Furthermore, the expression of ZAPHIR in solid tumor cell lines indicates the involvement of ZAPHIR-specific CD8+ T cell responses in selective GVT immunity. These findings illustrate that the ZNF419-encoded MiHA ZAPHIR is an attractive target for specific immunotherapy after allogeneic SCT

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:3125305
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2005). A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
  2. (1999). A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia.
  3. (2008). Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: application for allogeneic transplantation.
  4. (2009). Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cellmediated lysis.
  5. (2002). Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen - A pilot study in patients with refractory malignancies.
  6. (2004). Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
  7. (1998). Allogeneic peripheral-blood progenitor-cell transplantation for poor- risk patients with metastatic breast cancer.
  8. (2002). Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
  9. (2007). Alternative splicing due to an intronic SNP in HMSD generates a novel minor histocompatibility antigen.
  10. (2008). C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.
  11. (2009). Efficient activation of LRH-1-specific CD8+ T-cell responses from transplanted leukemia patients by stimulation with P2X5 mRNA-electroporated dendritic cells.
  12. (1999). Feasibility of immunotherapy of relapsed leukemia with ex vivo- generated cytotoxic T lymphocytes specific for hematopoietic system- restricted minor histocompatibility antigens.
  13. (2009). Graft-versus-host disease.
  14. (1990). Graft-versus-leukemia reactions after bone marrow transplantation.
  15. (2003). Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA2-specific T cells can induce complete remissions of relapsed leukemia.
  16. (2010). High Throughput Characterization of 10 New Minor Histocompatibility Antigens by Whole Genome Association Scanning.
  17. (1997). Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.
  18. (2003). Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens.
  19. (2006). Immunotherapy for renal cell cancer.
  20. (2002). Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion.
  21. (2004). Minors come of age: Minor histocompatibility antigens and graft-versus-host disease.
  22. (2004). Molecules and mechanisms of the graft-versusleukaemia effect.
  23. (2004). New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population.
  24. (2000). Peptide-MHC class I tetrameric complexes display exquisite ligand specificity.
  25. (2008). Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.
  26. (2000). Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
  27. (2010). siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells.
  28. (2008). Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors.
  29. (1998). The minor histocompatibility antigen HA-1: a diallelic gene with a single amino acid polymorphism.
  30. (2001). Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells.